Severe bone complications of primary hyperparathyroidism in a young patient with the rare verified mutation of MEN1

Multiple endocrine neoplasia type 1 syndrome (MEN1) is a rare inherited disorder that can include combinations of more than 20 endocrine and non-endocrine tumors. Unfortunately, none of the described MEN1 mutations has been associated with a peculiar clinical phenotype, even within members of the same family, thus a genotype-to-phenotype correlation does not exist. MEN1 syndrome is the most common cause of hereditary primary hyperparathyroidism (PHPT), the disease penetrance of which exceeds 50% by the age of 20 and reaches 95% by the age of 40. At the same time, PHPT with hyperplasia or adenomas of the parathyroid glands (PTG) is the most distinctive manifestation of the MEN1 syndrome. One of the main symptoms of PHPT, both in sporadic and hereditary forms of the disease, is bone damage. At the time of diagnosis in PHPT/MEN1, the bone mineral density is generally lower in comparison with the sporadic form of PHPT. This may be due to excessive secretion of parathyroid hormone during the period of peak bone mass, concomitant components of the syndrome, extended surgical treatment, and the direct effect of a mutation in the menin gene on bone remodeling. This clinical case describes a young patient with severe bone complications of PHPT and uncertain rare MEN1 mutation. PHPT was diagnosed five years later from the first onset of bone complications and repeated orthopedic operations. There was the «hungry bones» syndrome after successful surgery of PHPT, which was managed with vitamin D and calcium carbonate supplementation and there is a positive dynamic in increased bone mineral density in the main skeleton after 6 months.

1. Kamilaris CDC, Stratakis CA. Multiple endocrine neoplasia type 1 (MEN1): An update and the significance of early genetic and clinical diagnosis. Frontiers in Endocrinology. 2019;10:339. doi: https://doi.org/10.3389/fendo.2019.00339.

2. Mele C, Mencarelli M, Caputo M, et al. Phenotypes Associated With MEN1 Syndrome: A Focus on Genotype-Phenotype Correlations. Frontiers in Endocrinology. 2020;11:591501. doi: https://doi.org/10.3389/fendo.2020.591501.

3. Al-Salameh A, Cadiot G, Calender A, et al. Clinical aspects of multiple endocrine neoplasia type 1. Nature Reviews Endocrinology. 2021;17(4):207-224. doi: https://doi.org/10.1038/s41574-021-00468-3.

4. Gorbacheva AM, Eremkina AK, Mokrysheva NG. Hereditary Syndromal and Nonsyndromal Forms of Primary Hyperparathyroidism. Problems of Endocrinology. 2020;66(1):23-34 (In Russ.). doi: /https://doi.org/10.14341/probl10357.

5. Thakker RV, Newey PJ, Walls GV, et al. Clinical Practice Guidelines for Multiple Endocrine Neoplasia Type 1 (MEN1). The Journal of Clinical Endocrinology & Metabolism. 2012;97(9):2990-3011. doi: https://doi.org/10.1210/jc.2012-1230.

6. Eller-Vainicher C, Chiodini I, Battista C, et al. Sporadic and MEN1- Related Primary Hyperparathyroidism: Differences in Clinical Expression and Severity. Journal Bone and Mineral Research. 2009;24(8):1404-1410. doi: https://doi.org/10.1359/JBMR.090304.

7. Kong J, Wang O, Nie M, et al. Clinical and Genetic Analysis of Multiple Endocrine Neoplasia Type 1-Related Primary Hyperparathyroidism in Chinese. PLoS ONE. 2016;11(11):166634. doi: https://doi.org/10.1371/journal.pone.0166634.

8. Witteveen JE, van Thiel S, Romijn JA, Hamdy NAT. Hungry bone syndrome: still a challenge in the post-operative management of primary hyperparathyroidism: a systematic review of the literature. European Journal of Endocrinology. 2013;168(3):45-53. https://doi.org/10.1530/EJE-12-0528.

9. Silva AM, Vodopivec D, Christakis I, et al. Operative intervention for primary hyperparathyroidism offers greater bone recovery in patients with sporadic disease than in those with multiple endocrine neoplasia type 1–related hyperparathyroidism. Surgery (United States). 2017:107-115. https://doi.org/10.1016/j.surg.2016.06.065.

10. Norton JA, Venzon DJ, Berna MJ, et al. Prospective Study of Surgery for Primary Hyperparathyroidism (HPT) in Multiple Endocrine Neoplasia-type 1 (MEN1), and Zollinger-Ellison syndrome (ZES): Long-term Outcome of a More Virulent form of HPT. Annals of Surgery. 2008;247(3):501-10. https://doi.org/10.1097/SLA.0b013e31815efda5.

11. Burgess JR, David R, Greenaway TM, et al. Osteoporosis in multiple endocrine neoplasia type 1: Severity, clinical significance, relationship to primary hyperparathyroidism, and response to parathyroidectomy. Arch Surg. 1999;134(10):1119−1123. https://doi.org/10.1001/archsurg.134.10.1119.

12. Lourenço DM, Toledo RA, Mackowiak II, et al. Multiple endocrine neoplasia type 1 in Brazil: MEN1 founding mutation, clinical features, and bone mineral density profile. European Journal of Endocrinology. 2008;159:259-274. https://doi.org/10.1530/EJE-08-0153.

13. Balsalobre Salmeron M, Rodriguez Gonzalez JM, Rios A et al. Primary hyperparathyroidism associated with MEN 1: Experience in 71 cases. Cirugia Espanola. 2018;96(10):627-633. https://doi.org/10.1016/j.ciresp.2018.06.014.

14. Mokrysheva NG, Dobreva EA, Maganeva IS, et al. Primary hyperparathyroidism in Russia according to the registry. Problems of Endocrinology. 2019;65(5):300-310. (In Russ.). https://doi.org/10.14341/probl9946.

15. Lamas C, Navarro E, Casterás A, et al. MEN1-associated primary hyperparathyroidism in the Spanish Registry: clinical characterictics and surgical outcomes. Endocr Connect. 2019;8(10):1416-1424. https://doi.org/10.1530/EC-19-0321.

16. Crabtree JS, Scacheri PC, Ward JM, et al. A mouse model of multiple endocrine neoplasia, type 1, develops multiple endocrine tumors. Proc Natl Acad Sci U S A. 2001;98:1118-1123. https://doi.org/10.1073/pnas.98.3.1118.

17. Sowa H, Kaji H, Canaff L, et al. Inactivation of menin, the product of the multiple endocrine neoplasia type 1 gene, inhibits the commitment of multipotential mesenchymal stem cells into the osteoblast lineage. Journal of Biological Chemistry. 2003;278(23):21058-21069. https://doi.org/10.1074/jbc.M302044200.

18. Sowa H, Kaji H, Hendy GN, et al. Menin is required for bone morphogenetic protein 2and transforming growth factor β-regulated osteoblastic differentiation through interaction with Smads and Runx2. Journal of Biological Chemistry. 2004;279(39):40267-40275. https://doi.org/10.1074/jbc.M401312200.

19. Naito J, Kaji H, Sowa H, et al. Menin suppresses osteoblast differentiation by antagonizing the AP-1 factor, JunD. Journal of Biological Chemistry. 2005;280(6):4785-4791. https://doi.org/10.1074/jbc.M408143200.

20. Zou ML, Chen ZH, Teng YY, et al. The Smad Dependent TGF-β and BMP Signaling Pathway in Bone Remodeling and Therapies. The Smad DependentTGF-βand BMP Signaling Pathway inBone Remodeling and Therapies. Front. Mol. Biosci. 2021;8:593310. https://doi.org/10.3389/fmolb.2021.593310.

21. Hill CS. Transcriptional Control by the SMADs. Cold Spring Harb Perspect Biol. 2016; 8(10):a022079. https://doi.org/10.1101/cshperspect.a022079.

22. Maraghelli D, Giusti F, Marini F, et al. Bone tissue and mineral metabolism in hereditary endocrine tumors: Clinical manifestations and genetic bases. Orphanet Journal of Rare Diseases. 2020;15(1). https://doi.org/10.1186/s13023-020-01380-1.

23. Rostomyan LG, Mokrysheva NG, Tyulpakov AN, et al. Features of bone metabolism in the syndrome of multiple endocrine neoplasia type 1. Obesity and metabolism. 2009;6(4):42-46. (In Russ.). https://doi.org/10.14341/2071-8713-4878.

24. Misiorowski W, Czajka-Oraniek I, Kochman M, et al. Osteitis fibrosa cystica — a forgotten radiological feature of primary hyperparathyroidism. Endocrine. 2017;58:380-385. https://doi.org/10.1007/s12020–017–1414–2.

25. Buryakina SA, Tarbaeva NV, Volevodz NN, et al. Computed tomographic diagnostics of hyperparathyroidism. Therapeutic archive. 2018;90(4):60-66. (In Russ.). http://doi.org/10.26442/terarkh201890460-66.

26. Jarrar SM, Daoud SS, Jbarah OF, Albustami IS. Paraparesis as a rare first presentation of primary hyperparathyroidismrelated brown tumor in the thoracic spine: case report and literature review. Annals of Medicine and Surgery. 2021;63:102197. https://doi.org/10.1016/j.amsu.2021.102197.

27. Mamedova EO, Mokrysheva NG, Rozhinskaya LYa. Hereditary forms of primary hyperparathyroidism. Osteoporosis and Bone Diseases. 2018;21(2):23-29. (In Russ.). doi:10.14341/osteo9877.

28. Przhiyalkovskaya EG, Mamedova EO, Pigarova EA, et al. Pituitary adenomas in the framework of hereditary syndromes. Problems of Endocrinology. 2014;60(4):51-59. (In Russ.). https://doi.org/10.14341/probl201460451-59.

29. Mokrysheva NG, Eremkina AK, Krupinova JA, et al. The clinical practice guidelines for primary hyperparathyroidism, short version. Problems of Endocrinology. 2021;67(4):94-124. (In Russ.). https://doi.org/10.14341/probl12801.

30. Coutinho FL, Lourenco DM Jr, Toledo RA, et al. Post-surgical followup of primary hyperparathyroidism associated with multiple endocrine neoplasia type 1. Clinics (Sao Paulo). 2012;67(1):169-72. https://doi.org/10.6061/clinics/2012(sup01)28.

31. Wang W, Nie M, Jiang Y, et al. Impaired geometry, volumetric density, and microstructure of cortical and trabecular bone assessed by HR-pQCT in both sporadic and MEN1-related primary hyperparathyroidism. Osteoporos Int. 2020;31(1):165-173. https://doi.org/10.1007/s00198-019-05186-1.

32. Marini F, Giusti F, Cioppi F, et al. Bone and Mineral Metabolism Phenotypes in MEN1-Related and Sporadic Primary Hyperparathyroidism, before and after Parathyroidectomy. Cells. 2021;10:1895. https://doi.org/10.3390/cells10081895

33. Atabek ME, Pirgon O, Sert A, Esen HH. Extensive brown tumors caused by parathyroid adenoma in an adolescent patient. European Journal of Pediatrics. 2008;167(1):117-119. https://doi.org/10.1007/s00431-007-0414-2.